EP1603583A2 - Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique - Google Patents

Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique

Info

Publication number
EP1603583A2
EP1603583A2 EP04721524A EP04721524A EP1603583A2 EP 1603583 A2 EP1603583 A2 EP 1603583A2 EP 04721524 A EP04721524 A EP 04721524A EP 04721524 A EP04721524 A EP 04721524A EP 1603583 A2 EP1603583 A2 EP 1603583A2
Authority
EP
European Patent Office
Prior art keywords
acid
boswellic acid
keto
dihydroboswellic
boswellic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04721524A
Other languages
German (de)
English (en)
Inventor
Frank Striggow
Werner Schmidt
Till Mack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KeyNeurotek AG
Original Assignee
KeyNeurotek AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2003111920 external-priority patent/DE10311920A1/de
Priority claimed from DE2003111921 external-priority patent/DE10311921A1/de
Priority claimed from DE10331750A external-priority patent/DE10331750A1/de
Application filed by KeyNeurotek AG filed Critical KeyNeurotek AG
Publication of EP1603583A2 publication Critical patent/EP1603583A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense

Definitions

  • the invention relates to the use of frankincense or components thereof, which may optionally be hydrogenated, for the prophylaxis and / or treatment of cerebral ischemia and / or skull / brain trauma.
  • the hydrogenation products of frankincense or the components thereof are particularly advantageous in the prophylaxis and / or treatment of Alzheimer's disease.
  • the invention thus relates in particular to the use of the hydrogenation products of frankincense (olibanum), its hydrogenated ingredients and physiologically acceptable salts and derivatives thereof for the manufacture of a medicament for the prophylaxis and / or treatment of cerebral ischemia, skull / brain trauma and / or Alzheimer's disease.
  • the invention further relates to the use of frankincense or components of the frankincense for the manufacture of a medicament for the prophylaxis and / or treatment of cerebral ischemia and / or traumatic brain injury (TBI).
  • TBI traumatic brain injury
  • Ischemia is the interruption of the blood supply to cells, tissues or organs. This situation is particularly critical when a continuous supply of oxygen and / or nutrients (e.g. glucose) is necessary. This applies in particular to the central nervous system (CNS), since nerve cells in particular are extremely sensitive to an interruption in the oxygen and glucose supply. Short-term ischemia, e.g. as a result of a stroke or a heart attack, leads to neuronal cell death in the affected brain areas.
  • oxygen and / or nutrients e.g. glucose
  • Skull / brain trauma is a combined injury to the head, skull and brain, although the external covering may remain intact.
  • the general distinction is between open skull / brain trauma and covered skull / brain trauma distinguished, with an open skull / brain trauma, the dura is destroyed, so that CSF and / or brain matter escapes.
  • a distinction is made between blunt or covered brain trauma, in which the dura is not destroyed.
  • Alzheimer's disease is a degenerative disease with morphological and biochemical changes in brain areas. It represents a progressive atrophy of the large cortex with senile plaques, degeneration of neurofibrils and conophilic angiopathy. The symptoms of Alzheimer's disease include disorientation with impaired cognitive abilities, memory loss, total regression to dementia. Biochemically, a disturbance of the cortical cholinergic system with a decrease in the choline acetylase (reduced acetylcholine synthesis) can be demonstrated.
  • Alzheimer's disease The causes of the development of Alzheimer's disease are unclear. Genetic, metabolic or even "slow virus infections" are the main topics discussed. So far, no targeted therapeutic agents are available. The therapeutic options extend above all to the relief of illness-related symptoms.
  • the cholinesterase inhibitor tacrine is used to treat Alzheimer's disease, which is said to improve cognitive performance. Therapy with this active ingredient is unsatisfactory due to its low response rate and its strong side effects during long-term therapy. There is therefore a strong need for a treatment method that at least progresses in the atrophy of the brain in Alzheimer's Patient delayed. There is also a need for a drug whose active ingredient has a high availability at the target organ (brain) and is well tolerated, especially in long-term therapy.
  • frankincense is already known in folk medicine for the treatment of various diseases, especially inflammation and rheumatism, especially in Chinese and Indian folk medicine.
  • Frankincense or olibanum is understood to mean a gum resin that can be obtained from the bark of the trees Boswellia carteri, Boswellia serrata and other species that are native to Arabia and Somalia.
  • the resin typically contains 5 to 9% of the olibanum oil (or frankincense oil), 15 to 16% resin acids, 25 to 30% ether-insoluble compounds and 45 to 55% ether-soluble compounds, especially the triterpenoid boswellic acids, mainly ß-boswellic acid.
  • Boswellic acid is often referred to as boswellic acid in the literature.
  • frankincense A mixture of the resins of the balsam family Boswellia sacra (southern Arabia), Boswellia carteri and Boswellia frereana (both Somalia) is often referred to as frankincense or olibanum.
  • Indian frankincense (“Salai Guggal”) is also known, which is obtained from extracts of the resin from Boswellia serrata (India).
  • Salai Guggal is a herbal mixture of many substances. It contains essential oils (various mono-, di- and sesquiterpenes), mucus (e.g. galactose, arabinose,
  • Mannose, xylose Mannose, xylose
  • pharmacologically active resin substances pentacyclic and tetracyclic triterpenes, Boswellic acids or Tirucallen acids
  • Boswellia serrata essentially contains the following ingredients: ⁇ -boswellic acid, acetyl- ⁇ -boswellic acid, acetyl-11-keto- ⁇ -boswellic acid , 11-keto-ß-boswellic acid and to a lesser extent ⁇ - and ß-boswellic acid as well as the tirucallic acids.
  • ⁇ -boswellic acid acetate and ⁇ -boswellic acid acetate and their analogues inhibit topoisomerase-I and topoisomerase-II. Therefore, this document suggests using the compounds to treat various types of cancer.
  • frankincense, frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives and their physiological salts, pure boswellic acid, a physiologically acceptable salt, a derivative and a salt of the derivative can be used in the treatment of Alzheimer's disease.
  • DE-A 44 45 728 uses pure boswellic acid, physiologically acceptable salts thereof, derivatives thereof or salts of the derivatives and herbal preparations which contain boswellic acid for the treatment of brain tumors.
  • WO 97/07796 uses boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a boswellic acid-containing plant preparation for the prophylaxis and / or combating of diseases which are caused by increased leukocyte elastase or piasmin activity.
  • This publication therefore proposes to use the compounds in the treatment of diseases such as, for example, pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis, chronic bronchitis, glomerulonephritis and rheumatoid arthritis, and also to inhibit the growth and metastasis of many types of cancer.
  • WO 02/15916 and the priority-establishing DE-A 100 41 217 disclose didydroboswellic acids, physiologically acceptable salts thereof and hydrogenated extracts from Boswellia. They propose to use these compounds for the prophylactic and / or therapeutic treatment of undesirable physical and mental conditions, in particular of somatic, psychosomatic and psychological disorders such as, for example, inflammatory processes which are caused by increased leukotriene formation, leukocyte elastase or piasmin activity.
  • the abovementioned diseases are, for example, inflammatory joint diseases, epidermal lesions, allergic and chronic asthma, endotoxin shock, inflammatory bowel diseases, chronic hepatitis, pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis, chronic bronchitis, glomerulonephritis and rheumatic tumors as well as rheumatic tumors and rheumatoid arthritis.
  • Another object of the invention is also to provide a medicament which has a high bioavailability at the target organ and which, in addition to an excellent effectiveness in the treatment of cerebral ischemia and head / brain trauma, is used particularly advantageously in the treatment of Alzheimer's disease can be.
  • the invention thus provides on the one hand the use of frankincense, frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives and their physiologically acceptable salts, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a derivative the boswellic acid or a boswellic acid-containing herbal preparation for the manufacture of a medicament for the prophylactic and / or therapeutic treatment of skull / brain trauma and / or cerebral ischemia for Available, but also the use of the hydrogenation products of frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives and their physiologically acceptable salts, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a derivative of boswellic acid or a herbal preparation containing boswellic acid for the manufacture of a medicament for the prophylactic
  • the medicinal products can advantageously also be used for the prophylaxis and treatment of cerebral damage from stroke, heart attack or after an operation.
  • frankincense in particular frankincense extracts and substances contained in frankincense, and their derivatives, in each case optionally in the salt form, and the hydrogenation products of the above compounds and active mixtures are outstandingly suitable for preventing and / or treating cerebral ischemia and head / brain trauma are.
  • frankincense and frankincense extracts are known as traditional natural remedies or as medicinal products for the treatment of various mental and physical conditions
  • the literature does not provide any information about the availability of the active substances contained in the target organ (place of action). This so-called bioavailability is particularly important in the prophylaxis and / or treatment of diseases that affect the brain.
  • An effective active ingredient should namely be able to penetrate the blood / brain barrier, which can lead to an increase in activity with the same or lower dosage of the drug.
  • acetyl-11-keto- ⁇ -boswellic acid AKBA
  • 11-keto- ⁇ -boswellic acid KBA
  • ⁇ -boswellic acid ß-boswellic acid can contain small amounts of ⁇ - or ⁇ -boswellic acid
  • ß-boswellic acid can be obtained in a manner known per se from plants containing boswellic acid, in particular from Boswellia serrata.
  • Boswellia species are Boswellia papyrifera, Boswellia frereana, Boswellia carteri, Boswellia thunfera or Boswellia glabra, however other representatives of the Boswellia family can also be used.
  • Physiologically acceptable salts of boswellic acid are preferably the sodium, potassium, ammonium and calcium salts.
  • Preferred derivatives of boswellic acid are C. -C 6 - Alkyl esters in which the carboxyl group of boswellic acid has been esterified with an appropriate alcohol. Methyl esters, ethyl esters, n-propyl esters, / so-propyl esters, n-butyl esters, / so-butyl esters and feit-but esters are particularly preferred.
  • the hydroxyl group of the boswellic acid has been esterified with a physiologically acceptable carboxylic acid, preferably with a C .- to C 2 o, in particular with a d- C 6 carboxylic acid, in particular formic acid or acetic acid.
  • a physiologically acceptable carboxylic acid preferably with a C .- to C 2 o, in particular with a d- C 6 carboxylic acid, in particular formic acid or acetic acid.
  • Derivatives of boswellic acid which are preferably used according to the invention are ⁇ -boswellic acid acetate.
  • herbal preparations in particular frankincense or frankincense extracts, are preferably used for the production of the medicaments for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or skull / brain trauma.
  • the extracts preferably contain one or more of the aforementioned compounds.
  • frankincense or frankincense extracts which contain boswellic acid, in particular ⁇ -boswellic acid, for the production of a medicament for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or skull / brain trauma.
  • Boswellic acids in particular ⁇ -boswellic acid
  • Boswellia serrata can be obtained in a manner known per se from plants containing boswellic acid, in particular from Boswellia serrata.
  • Other suitable Boswellia species are Boswellia papyrifera, Boswellia frereana, Boswellia carteri, Boswellia thurifera or Boswellia glabra, however other members of the Boswellia family can also be used.
  • the frankincense used or the frankincense extracts used according to the invention preferably contain ⁇ -boswellic acid and / or acetyl- ⁇ -boswellic acid and / or acetyl-11-keto- ⁇ -boswellic acid and / or 11-keto- ⁇ -boswellic acid ,
  • Herbal preparations which according to the invention can preferably be used for the production of the medicaments for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or skull / brain trauma are commercially available, for example from Ayurmedica, Pöcking, for example under the name H15.
  • This is a lipophilic extract from Boswellia serrata, which contains a dry extract from Olibanum as the active ingredient.
  • the product is available as a tablet or as granules. According to DE-A 44 44 288, one tablet contains 400 mg of dry extract from olibanum (4.2-5.9: 1), extracting agent: chloroform / methanol. 1 g of granules contains 500 mg of dry extract from olibanum (4.2-5.9: 1), extracting agent: chloroform / methanol.
  • ingredients of frankincense in particular acetyl-11-keto-ß-boswellic acid and / or 11-keto-ß-boswellic acid and / or ß-boswellic acid, optionally in a mixture with ⁇ - and / or ⁇ -boswellic acid and / or one or more of the derivatives of boswellic acid preferably used according to the invention as described above for the manufacture of the medicament for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or Skull / brain trauma can be used.
  • active substances and active substance compositions which are preferred according to the invention and which can be used to prepare the medicaments for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or skull / brain trauma are described, for example, in DE-A 44 44 288 and DE-A 44 45 728 described, to which extent reference is made.
  • Preferred boswellic acids and Derivatives of boswellic acids are also described in DE-A 42 01 903, to which reference is also made in this respect.
  • the active substances and active substance compositions which are described in DE-A 4444 288 are preferred.
  • a plant extract which has been obtained from frankincense for example by ethanolic extraction.
  • the medicament for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or skull / brain trauma can contain further active substances, in particular further herbal active substances, in addition to the active substances based on frankincense defined here.
  • the hydrogenation products of the incense are very well absorbed and can penetrate the blood / brain barrier sufficiently so that a sufficient concentration of the active compounds in the target organ can be achieved, the activity of the products being essentially retained, advantageously even being improved ,
  • the hydrogenation products of frankincense, its ingredients and the physiologically acceptable salts and derivatives of these hydrogenation products, but also hydrogenated frankincense extracts, are suitable for producing a medicament according to the invention for the prophylactic and / or therapeutic treatment of cerebral ischemia, skull / brain trauma and / or Alzheimer's disease.
  • Also suitable according to the invention are the hydrogenation products of acetyl-11-keto- ⁇ -boswellic acid, 11-keto- ⁇ -boswellic acid or ⁇ -boswellic acid, the latter being able to contain small amounts of ⁇ - or ⁇ -boswellic acid. Also suitable according to the invention are hydrogenation products of ß-boswellic acid acetate, ß-boswellic acid formate, ß-boswellic acid methyl ester, acetyl-ß-boswellic acid, but also of the boswellic acids and derivatives of boswellic acids described in DE-A 42 01 903, to which reference is made in this regard becomes.
  • Dihydroboswellic acids their physiologically acceptable salts, derivatives thereof as well as physiological salts of the derivatives, in particular ⁇ -dihydroboswellic acid acetate, ⁇ -dihydroboswellic acid methyl ester, ⁇ -dihydroboswellic acid methyl ester, acetyl- ⁇ -dihydroboswellic acid, ⁇ -dihydro acid acid, ⁇ -dihydrogen acid, ⁇ -dihydro acid, ⁇ -di-dihydroic acid, ⁇ -di-dihydro-well acid, ⁇ -di-dihydro-well acid, ⁇ -di-dihydro-well acid, ⁇ -di-dihydro-well acid, ⁇ -di-dihydro-well acid, ⁇ -di-dihydro-well acid, ⁇ -di-dihydro-diacid, ⁇ -di-dihydro-well acid Formyl dihydroboswellic acid can be
  • the hydrogenation products which can be used according to the invention can be obtained by hydrogenation, preferably by catalytic hydrogenation.
  • the hydrogenation of these compounds is carried out in a manner known to the person skilled in the art, preferably in such a way that the basic structure of the compound is selectively hydrogenated. Such a method is described for example in WO 02/15916.
  • a hydrogenated plant extract obtained from frankincense for example by ethanolic extraction, can also be used to produce the medicament according to the invention for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or skull / brain trauma and / or Alzheimer's disease.
  • the physiologically acceptable salts of the hydrogenation products according to the invention are understood to be the sodium, potassium, ammonium and calcium salts of the abovementioned compounds.
  • C.-C 6 alkyl esters are the derivatives Understand dihydroboswellic acid in which the carboxyl group of dihydroboswellic acid has been esterified with a corresponding alcohol.
  • dihydroboswellic acid alkyl esters are, for example, the methyl ester, ethyl ester, n-propyl ester, / so-propyl ester, ⁇ -butyl ester, / so-butyl ester and fe / t-butyl ester.
  • hydroxyl group of dihydroboswellic acid prefferably esterified with a physiologically tolerable carboxylic acid, for example with a C to C 20 , in particular with a C.-C 6, carboxylic acid, in particular with formic acid or acetic acid.
  • a physiologically tolerable carboxylic acid for example with a C to C 20 , in particular with a C.-C 6, carboxylic acid, in particular with formic acid or acetic acid.
  • Herbal preparations that can be used to produce the hydrogenation products according to the invention are commercially available, for example from Ayurmedica, Pöcking, for example under the name H15.
  • hydrogenation products from other preparations with frankincense extract can also be used; in particular, according to the invention, hydrogenation products of synthetically produced or naturally obtained ingredients of frankincense, in particular acetyl-11-keto-ß-boswellic acid and / or 11-keto-ß- boswellic acid and / or ⁇ -boswellic acid, optionally in a mixture with ⁇ - and / or ⁇ -boswellic acid and / or one or more of the derivatives of boswellic acid which are preferably used according to the invention, as described above, can be used for the preparation of the medicament.
  • synthetically produced or naturally obtained ingredients of frankincense in particular acetyl-11-keto-ß-boswellic acid and / or 11-keto-ß- boswellic acid and / or ⁇ -boswellic acid, optionally in a mixture with ⁇ - and / or ⁇ -boswellic acid and / or one or more
  • Active substances and active substance compositions which are suitable according to the invention and which can be used to produce the medicaments according to the invention with the hydrogenation products are described, for example, in WO 02/15916, to which reference is made in this regard.
  • the medicament for the prophylactic and / or therapeutic treatment of cerebral ischemia and / or skull / brain trauma and / or Alzheimer's disease can contain further active substances, in particular further herbal active substances, in addition to the active substances based on frankincense defined here.
  • hydrogenation products from other preparations with frankincense extract can also be used; in particular, according to the invention, hydrogenation products can also be synthetically produced or in a natural way Incense ingredients obtained, in particular acetyl-11-keto-ß-boswellic acid and / or 11-keto-ß-boswellic acid and / or ß-boswellic acid, optionally in a mixture with ⁇ - and / or ⁇ -boswellic acid and / or one or more the boswellic acid derivatives preferably used according to the invention, as described above, can be used for the preparation of the medicament.
  • the medicament is preferably formulated according to the invention in such a way that it is present in unit doses which can be administered orally, one or more times a day, in particular one to four times a day, preferably.
  • the medicaments can be formulated in a manner known per se for customary administration routes, for example as oral, parenteral, rectal, intranasal, intracranial or intrathecal administrations. Oral, parenteral, rectal and intranasal applications are preferred here. It is also possible that the formulations are designed for inhalation or insufflation. Formulations for intracranial or intrathecal administration are also possible.
  • the pharmaceuticals according to the invention can, for example, be in solid, semi-solid or liquid form.
  • they can be formulated in the form of tablets, granules or capsules which, in addition to the active substance or the active substance, also contain pharmaceutically acceptable additives, such as binders, fillers, lubricants, explosives or, if appropriate, wetting agents, and which can be coated.
  • medicaments which are in the form of tablets or granules or pellets, the granules or pellets generally being in conventional capsules.
  • the granules or tablets contain customary pharmaceutically acceptable additives such as binders, for example pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropylmethyl cellulose, fillers such as lactose, sucrose, mannitol, corn starch, microcrystalline cellulose or calcium hydrogenphosphate, lubricants such as stearic acid, polyethylene glycol .
  • Tablets, pellets or capsules can be coated in a manner known per se (for example with a water-soluble or enteric coating) or they can be present uncoated. Coated tablets are preferred.
  • the medicaments can be in the form of liquid preparations for oral administration.
  • Liquid preparations for oral administration can be present, for example, as aqueous or oily solutions, syrups, elixirs, emulsions or suspensions. It is also possible that formulations are available as a dry product for reconstitution with a suitable solvent, in particular water. The production of such liquid preparations is also known, and conventional additives such as e.g.
  • Suspension agents such as sorbitol, cellulose derivatives, glucose, sugar syrup, gelatin, aluminum stearate gel or hydrogenated edible fats, emulsifiers such as lecithin, gum arabic or sorbitan monooleate, non-aqueous vehicles such as almond oil, oily esters, ethyl alcohol or fractionated vegetable oils, preservatives or methyl or benzyl para-para Sorbic acid, buffers, flavoring and aroma agents, coloring and sweetening agents are present.
  • sorbitol cellulose derivatives, glucose, sugar syrup, gelatin, aluminum stearate gel or hydrogenated edible fats
  • emulsifiers such as lecithin, gum arabic or sorbitan monooleate
  • non-aqueous vehicles such as almond oil, oily esters, ethyl alcohol or fractionated vegetable oils, preservatives or methyl or benzyl para-para Sorbic acid, buffers, flavoring and aroma agents, coloring and sweetening
  • Medicaments according to the invention can also be formulated as preparations for injection in a manner known per se.
  • Preparations for injection in particular for intravenous, intramuscular, subcutaneous, intrathecal or intracranial injection, which are suitably present in unit dosage form such as ampoules or in multiple dose containers, are preferred according to the invention.
  • the formulations contain a customary preservative and other customary auxiliaries.
  • the medicaments according to the invention can also be prepared as suspensions, solutions or emulsions in oily or aqueous vehicles in a manner known to the person skilled in the art.
  • the preparations can be in the form of suspensions, solutions or emulsions in oily or aqueous vehicles and can contain customary auxiliaries such as suspending, stabilizing and / or dispersing agents and / or agents for adjusting the tonicity.
  • the agent is present as a dry powder for reconstitution in a suitable carrier.
  • Liquid sprays, nasal drops or snuff powder can be mentioned as intranasal drugs.
  • the compounds are made available, for example, as an aerosol spray.
  • the compounds or extracts according to the invention can be present in pressurized packs using suitable blowing agents.
  • the package will also contain a suitable dosing device.
  • Capsules or cartridges made of, for example, gelatin for use in an inhalation device or an insufflation device can be prepared in the usual way so that a powder mixture of a compound used according to the invention and a suitable powder base such as lactose or starch is used.
  • the medicinal products can be formulated in a corresponding manner.
  • Sprague Dawley rats 250-280g are clamped into a head stereotaxy under halothane inhalation anesthesia and the skin in the skull area is opened.
  • a hole (1 mm in diameter) is drilled in the cranial bones according to the coordinates: 0.90 mm anterior bregma, 5.2 mm lateral to the satura sagittalis.
  • a Hamilton syringe is now lowered from the dura mater 7.5 mm deep into the brain and 3 ⁇ l (90 pmol) endothelin 1 is injected into the vicinity of the central cerebral artery. Endothelin 1 has a vasoconstructive effect, which closes the vessel and thus induces the stroke.
  • Endothelin 1 has a vasoconstructive effect, which closes the vessel and thus induces the stroke.
  • the syringe is removed and the skin over the Skull bones sewn up. The animals are kept normothermal throughout the operation.
  • the animals are perfusion-fixed in deep pentobarbital anesthesia with 4% paraformaldehyde in 0.1 M phosphate buffer.
  • the brains are removed and 1 mm thick coronal sections are made in a rat brain matrix.
  • 20 ⁇ m thick cryostat sections are made, mounted on slides and stained with toluidine Nissl.
  • a light microscope Nekon, Eclipse TE 3000
  • image analysis software Lucia version 4.2.1 the cortical and striatal infarct area is determined and the infarct volume is calculated by multiplying by the section thickness.
  • the data are analyzed for statistical significance using Student's t-test.
  • the occlusion of the middle cerebral artery leads to the death of nerve cells in the brain regions of the cortex and striatum. 7 days after induction of cerebral ischemia and parallel administration of frankincense extract, a significant and significant reduction in the infarct volume can be observed compared to the untreated control group. This finding is surprising and new.
  • test groups were formed from eight test animals each, with group 1 being administered intraperitoneally with 10 mg / kg of frankincense extract two hours before induction of ischemia, six hours after reperfusion, on the third day after the operation and on the sixth day after the operation ,
  • Group 2 received an aqueous solution containing 10% ethanol and 0.9% sodium chloride intraperitoneally instead of frankincense extract, using the same administration regimen as for group 1.
  • Group 3 received no treatment, neither with frankincense extract nor with solvent, and group 4 was a control group in which no ischemia was induced.
  • the animals were perfusion-fixed in deep pentobarbital anesthesia with 4% paraformaldehyde in 0.1 M phosphate buffer, and the infarct volume was determined.
  • the brains were removed and 1 mm thick coronal sections were made in a rat brain matrix.
  • 20 ⁇ m thick cryostat sections were made, on one Slides were drawn up and stained with toluidine Nissl.
  • a light microscope Nemkon, Eclipse TE 3000
  • Lucia version 4.2.1 image analysis software the cortical and striatal trauma area was determined and the trauma volume was calculated by multiplying by the section thickness. The data were analyzed for statistical significance using Student's t-test.
  • the medication produced according to the invention can reduce the damage to cerebral tissue and the resulting neurological abnormalities as a result of a skull / brain trauma or that such damage can be prevented.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation des produits d'hydrogénation de l'encens (oliban), de ses composants hydrogénés, de ses dérivés et de ses sels physiologiquement tolérables, ainsi que d'extraits d'encens hydratés pour produire un médicament destiné à prévenir et/ou traiter une ischémie cérébrale, une lésion cérébrale traumatique et/ou la maladie d'Alzheimer. L'invention concerne en outre l'utilisation d'encens, d'extrait d'encens, de substances présentes dans l'encens, de leurs sels physiologiquement tolérables, de leurs dérivés et de sels physiologiquement tolérables de ceux-ci, d'acides boswelliques purs, d'acides tirucalliques ou d'autres triterpènes, de leurs sels physiologiquement tolérables, de leurs dérivés ou de sels de ceux-ci pour produire un médicament destiné à prévenir et/ou traiter une ischémie cérébrale et/ou une lésion cérébrale traumatique.
EP04721524A 2003-03-18 2004-03-18 Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique Withdrawn EP1603583A2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE2003111920 DE10311920A1 (de) 2003-03-18 2003-03-18 Verwendung von Weihrauch zur Behandlung von Schädel/Hirntrauma
DE10311921 2003-03-18
DE10311920 2003-03-18
DE2003111921 DE10311921A1 (de) 2003-03-18 2003-03-18 Verwendung von Weihrauch zur Behandlung von zerebraler Ischämie
DE10331750 2003-07-14
DE10331750A DE10331750A1 (de) 2003-07-14 2003-07-14 Verwendung der Hydrierungsprodukte von Weihrauch (Olibanum) zur Prophylaxe und/oder Behandlung von zerebraler Ischämie, Schädel/Hirntrauma und/oder Alzheimer-Krankheit
PCT/EP2004/002839 WO2004082699A2 (fr) 2003-03-18 2004-03-18 Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique

Publications (1)

Publication Number Publication Date
EP1603583A2 true EP1603583A2 (fr) 2005-12-14

Family

ID=33032851

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04721524A Withdrawn EP1603583A2 (fr) 2003-03-18 2004-03-18 Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique

Country Status (3)

Country Link
US (1) US7645461B2 (fr)
EP (1) EP1603583A2 (fr)
WO (1) WO2004082699A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029578A2 (fr) 2008-09-15 2010-03-18 Ganga Raju Gokaraju Compositions anti-inflammatoires synergiques comprenant des extraits de boswellia serrata
DE102009004436A1 (de) * 2008-10-15 2010-04-29 Aureliasan Gmbh Verwendung einer Tirucallensäure, einer Lupansäure oder einer Robursäure als Arzneimittel
US10940175B2 (en) 2009-07-18 2021-03-09 Compton Developments Ltd. Inhibitor of inflammatory conditions
ES2874862T3 (es) * 2009-07-18 2021-11-05 Compton Developments Ltd Extracto antiinflamatorio de Boswellia frereana
US12005094B2 (en) 2009-07-18 2024-06-11 Compton Developments Ltd. Inhibitor of inflammatory conditions
PH12012501787A1 (en) 2010-03-15 2012-12-10 Laila Nutraceuticals Boswellia oil, its fractions and compositions for enhancing brain function
EP2723357A4 (fr) 2011-06-21 2015-04-01 Bvw Holding Ag Dispositif médical comportant de l'acide boswellique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047532C (zh) * 1994-06-15 1999-12-22 王万树 一种抗头痛中成药及其制备方法
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
GB9704904D0 (en) * 1997-03-10 1997-04-30 Riley Fletcher Foundation The Essential oil composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004082699A2 *

Also Published As

Publication number Publication date
WO2004082699A3 (fr) 2005-02-10
US7645461B2 (en) 2010-01-12
WO2004082699A2 (fr) 2004-09-30
US20060177467A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
DE69018601T2 (de) Konzentrate von aktiven Verbindungen und Kombinationen von aktiven Verbindungen, ihre Verfahren zur Herstellung und Arzneimittel, die die Konzentrate oder die Kombinationen enthalten.
DE69636308T2 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
DE69317578T2 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69007035T2 (de) Extrakt von Ginkgo biloba-Blättern, sein Verfahren zur Herstellung und Arzneimittel, die es enthalten.
DE60017878T2 (de) Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind
EP0501205B1 (fr) Moyens antiphlogistiques
EP0854709B1 (fr) Utilisation d'acide de boswell et de ses derives pour inhiber l'activite normale ou accrue de l'elastase leucocytaire ou de la plasmine
DE69733089T2 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
EP0796103B1 (fr) Utilisation de l'encens pour le traitement de la maladie d'alzheimer
DE3511609C2 (fr)
DE69232516T2 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
DE69805096T2 (de) Verwendung von ginkgo biloba extrakten zur herstellung eines medikaments
WO2004082699A2 (fr) Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique
DE4028945A1 (de) Kawa-kawa-extrakt, verfahren zu seiner herstellung und seine verwendung
DE60125955T2 (de) Bioaktive fraktion von eurycoma longifolia
DE69017839T2 (de) NMDA-blockierende Verbindungen, pharmazeutische Präparate, deren Herstellung und Verwendung.
DE69326188T2 (de) Verwendung von N-Acylderivaten von Aminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von neurogenen endoneuralen Ödemen der peripheren Nerven
DE69630073T2 (de) (-)Hydroxycitrat enthaltende Verbindungen mit neuen therapeutischen Wirkungen
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
EP0845264A1 (fr) Extrait partiel ou total de Camellia sinensis L. non fermenté
DE3827953C2 (fr)
DE10311920A1 (de) Verwendung von Weihrauch zur Behandlung von Schädel/Hirntrauma
DE10311921A1 (de) Verwendung von Weihrauch zur Behandlung von zerebraler Ischämie
DE69426317T2 (de) Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation
DE602004003955T2 (de) Nasale pharmazeutische zusammensetzung von piribedil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050916

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100812

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101223